Tanios Bekaii-Saab, MD, Mayo Clinic
Articles by Tanios Bekaii-Saab, MD, Mayo Clinic
Exciting Treatment Opportunities in mCRC
ByTanios Bekaii-Saab, MD, Mayo Clinic,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Joleen Hubbard, MD, Mayo Clinic,Kanwal Raghav, MD, MBBS, The University of Texas MD Anderson Cancer Center,John H. Strickler, MD, Duke Cancer Institute Closing out a discussion on novel therapies used to individualize treatment for patients with metastatic colorectal cancer, a panel of gastrointestinal oncologists highlight the most exciting treatment opportunities being explored to address current gaps in care.
Decisions for Sequencing Therapy for HER2-Expressing mCRC
ByTanios Bekaii-Saab, MD, Mayo Clinic,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Joleen Hubbard, MD, Mayo Clinic,Kanwal Raghav, MD, MBBS, The University of Texas MD Anderson Cancer Center,John H. Strickler, MD, Duke Cancer Institute Considerations regarding best sequencing strategies with novel therapies to treat HER2-mutated metastatic colorectal cancer.
Novel Therapies for HER2-Expressing mCRC
ByTanios Bekaii-Saab, MD, Mayo Clinic,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Joleen Hubbard, MD, Mayo Clinic,Kanwal Raghav, MD, MBBS, The University of Texas MD Anderson Cancer Center,John H. Strickler, MD, Duke Cancer Institute Implications for treating patients with HER2-expressing metastatic colorectal cancer with novel agents such as trastuzumab deruxtecan and tucatinib.
Novel Combinations Being Investigated for mCRC Treatment
ByTanios Bekaii-Saab, MD, Mayo Clinic,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Joleen Hubbard, MD, Mayo Clinic,Kanwal Raghav, MD, MBBS, The University of Texas MD Anderson Cancer Center,John H. Strickler, MD, Duke Cancer Institute Current trials exploring novel combinations that show potential in making microsatellite stable tumors hot and amenable to response to immunotherapy in metastatic colon cancer.
Dual I-O Therapy for mCRC
ByTanios Bekaii-Saab, MD, Mayo Clinic,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Joleen Hubbard, MD, Mayo Clinic,Kanwal Raghav, MD, MBBS, The University of Texas MD Anderson Cancer Center,John H. Strickler, MD, Duke Cancer Institute Drs Cathy Eng and Joleen M. Hubbard discuss the rationale for studying dual immunotherapy approaches for metastatic colorectal cancer treatment.
Best Practices Surrounding IO Treatment for mCRC
ByTanios Bekaii-Saab, MD, Mayo Clinic,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Joleen Hubbard, MD, Mayo Clinic,Kanwal Raghav, MD, MBBS, The University of Texas MD Anderson Cancer Center,John H. Strickler, MD, Duke Cancer Institute Kanwal Raghav, MD, MBBS, of The University of Texas MD Anderson Cancer Center, discusses when it is most appropriate to initiate immunotherapy for metastatic colorectal cancer, highlighting the roles of tumor mutation burden and microsatellite instability as biomarkers for treatment.
Frontline I-O Treatment for mCRC
ByTanios Bekaii-Saab, MD, Mayo Clinic,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Joleen Hubbard, MD, Mayo Clinic,Kanwal Raghav, MD, MBBS, The University of Texas MD Anderson Cancer Center,John H. Strickler, MD, Duke Cancer Institute Cathy Eng, MD, FACP, FASCO, describes data revealed by the KEYNOTE-177 trial and discusses best practices for using immunotherapy as first-line treatment of metastatic colorectal cancer.
Biomarker Testing and Precision Medicine in mCRC
ByTanios Bekaii-Saab, MD, Mayo Clinic,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Joleen Hubbard, MD, Mayo Clinic,Kanwal Raghav, MD, MBBS, The University of Texas MD Anderson Cancer Center,John H. Strickler, MD, Duke Cancer Institute A panel of gastrointestinal oncologists discuss current options for molecular testing based on the understanding that predictive biomarkers play a role in the management of metastatic colon cancer.
Fruquintinib for Refractory mCRC
ByTanios Bekaii-Saab, MD, Mayo Clinic,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Joleen Hubbard, MD, Mayo Clinic,Kanwal Raghav, MD, MBBS, The University of Texas MD Anderson Cancer Center,John H. Strickler, MD, Duke Cancer Institute Expectations regarding the use of fruquintinib, an oral VEGF tyrosine kinase inhibitor, as third-line therapy for metastatic colorectal cancer.
Best Strategies for Sequencing Regorafenib in mCRC
ByTanios Bekaii-Saab, MD, Mayo Clinic,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Joleen Hubbard, MD, Mayo Clinic,Kanwal Raghav, MD, MBBS, The University of Texas MD Anderson Cancer Center,John H. Strickler, MD, Duke Cancer Institute Considerations for how to sequence therapy with regorafenib for relapsed or refractory metastatic colorectal cancer based on the REVERCE II study.
TAS-102 for Refractory mCRC
ByTanios Bekaii-Saab, MD, Mayo Clinic,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Joleen Hubbard, MD, Mayo Clinic,Kanwal Raghav, MD, MBBS, The University of Texas MD Anderson Cancer Center,John H. Strickler, MD, Duke Cancer Institute Variables that impact patient selection for TAS-102 treatment as later-line therapy for metastatic colorectal cancer and considerations for using TAS-102 in combination with bevacizumab.
Regorafenib as Later-Line Treatment for mCRC
ByTanios Bekaii-Saab, MD, Mayo Clinic,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Joleen Hubbard, MD, Mayo Clinic,Kanwal Raghav, MD, MBBS, The University of Texas MD Anderson Cancer Center,John H. Strickler, MD, Duke Cancer Institute The rationale for treating metastatic colon cancer with regorafenib in a later-line setting and the importance of applying the dose-escalation strategy demonstrated by the ReDOS trial into clinical practice.
BRAF-Mutated mCRC: Treating With the BEACON Regimen
ByTanios Bekaii-Saab, MD, Mayo Clinic,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Joleen Hubbard, MD, Mayo Clinic,Kanwal Raghav, MD, MBBS, The University of Texas MD Anderson Cancer Center,John H. Strickler, MD, Duke Cancer Institute Gastrointestinal oncologists consider when it is most appropriate to initiate the BEACON trial regimen of encorafenib-binimetinib-cetuximab as treatment for BRAF-mutated metastatic colorectal cancer.
Applying Aggressive Therapy to Treat mCRC Up Front
ByTanios Bekaii-Saab, MD, Mayo Clinic,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Joleen Hubbard, MD, Mayo Clinic,Kanwal Raghav, MD, MBBS, The University of Texas MD Anderson Cancer Center,John H. Strickler, MD, Duke Cancer Institute The rationale for treating select patients with metastatic colorectal cancer with intensive therapy in the first-line setting vs waiting until disease progression.
Colorectal Cancer in a Younger Population
ByTanios Bekaii-Saab, MD, Mayo Clinic,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Joleen Hubbard, MD, Mayo Clinic,Kanwal Raghav, MD, MBBS, The University of Texas MD Anderson Cancer Center,John H. Strickler, MD, Duke Cancer Institute Cathy Eng, MD, FACP, FASCO, of Vanderbilt-Ingram Cancer Center reacts to the increasing rate of colorectal cancer among the younger population and highlights topics that apply specifically to counseling younger patients.
